2
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioma
7
Astrocytoma
4
Oligodendroglioma
2
Brain Neoplasms
2
Recurrence
1
Pathologic Processes
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoma, Follicular
1
Healthy Adult Participants
1
Disease Attributes
1
Interventions
Valproic Acid
2
Temozolomide
2
Oncolytic Virotherapy
2
Magnetic Resonance Spectroscopy
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
vorasidenib
1
trametinib
1
sonidegib
1
ribociclib
1
pembrolizumab
1
palbociclib
1
mirdametinib
1
interferon gamma-1b
1
imetelstat
1
gallium Ga 68 dotatate
1
fluorodopa F 18
1
fludarabine phosphate
1
fludarabine
1
Verteporfin
1
Thiotepa
1
Tacrolimus
1
Radiotherapy
1
ONC206
1
Mycophenolic Acid
1
Melphalan
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Immunologic Techniques
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Neuroepithelial
×
vorasidenib
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing